中国实用医刊
中國實用醫刊
중국실용의간
Chinese Journal of Practical Medicine
2015年
23期
25-26
,共2页
尿激酶%急性脑梗死%疗效%安全性
尿激酶%急性腦梗死%療效%安全性
뇨격매%급성뇌경사%료효%안전성
Urokinase%Acute cerebral infarction%Efficacy%Safety
目的 研究中、高剂量尿激酶静脉溶栓治疗6 h内急性脑梗死( ACI)的临床效果及安全性. 方法 将90例ACI患者抽签随机分为中剂量组与高剂量组,分别给予100万U、150万U尿激酶治疗,比较两组临床疗效、NHISS评分及不良反应发生情况. 结果 中剂量组总有效率为86.67%,高剂量组为91.11%,两组比较差异未见统计学意义(P>0.05);中剂量组溶栓前、溶栓6 h、溶栓10 d后NIHSS评分分别为(8.64 ±3.61)、(6.88 ±6.03)、(5.91 ±6.48)分;高剂量组分别为(8.58 ±3.24)、(6.94 ±6.31)、(6.03 ±6.44)分,两组比较差异均未见统计学意义( P>0.05 );中剂量组与高剂量组不良反应发生率比较差异未见统计学意义( P>0.05 ). 结论 高剂量尿激酶治疗6h内急性脑梗死均效果显著,均可改善神经缺损,但中剂量尿激酶不良反应发生率低,应作为优选治疗方案.
目的 研究中、高劑量尿激酶靜脈溶栓治療6 h內急性腦梗死( ACI)的臨床效果及安全性. 方法 將90例ACI患者抽籤隨機分為中劑量組與高劑量組,分彆給予100萬U、150萬U尿激酶治療,比較兩組臨床療效、NHISS評分及不良反應髮生情況. 結果 中劑量組總有效率為86.67%,高劑量組為91.11%,兩組比較差異未見統計學意義(P>0.05);中劑量組溶栓前、溶栓6 h、溶栓10 d後NIHSS評分分彆為(8.64 ±3.61)、(6.88 ±6.03)、(5.91 ±6.48)分;高劑量組分彆為(8.58 ±3.24)、(6.94 ±6.31)、(6.03 ±6.44)分,兩組比較差異均未見統計學意義( P>0.05 );中劑量組與高劑量組不良反應髮生率比較差異未見統計學意義( P>0.05 ). 結論 高劑量尿激酶治療6h內急性腦梗死均效果顯著,均可改善神經缺損,但中劑量尿激酶不良反應髮生率低,應作為優選治療方案.
목적 연구중、고제량뇨격매정맥용전치료6 h내급성뇌경사( ACI)적림상효과급안전성. 방법 장90례ACI환자추첨수궤분위중제량조여고제량조,분별급여100만U、150만U뇨격매치료,비교량조림상료효、NHISS평분급불량반응발생정황. 결과 중제량조총유효솔위86.67%,고제량조위91.11%,량조비교차이미견통계학의의(P>0.05);중제량조용전전、용전6 h、용전10 d후NIHSS평분분별위(8.64 ±3.61)、(6.88 ±6.03)、(5.91 ±6.48)분;고제량조분별위(8.58 ±3.24)、(6.94 ±6.31)、(6.03 ±6.44)분,량조비교차이균미견통계학의의( P>0.05 );중제량조여고제량조불량반응발생솔비교차이미견통계학의의( P>0.05 ). 결론 고제량뇨격매치료6h내급성뇌경사균효과현저,균가개선신경결손,단중제량뇨격매불량반응발생솔저,응작위우선치료방안.
Objective To study the clinical effect and safety of middle , high dose of intravenous thrombolytic therapy with urokinase on patients with 6 h acute cerebral infarction ( ACI ) .Methods Ninety cases of ACI patients were randomly divided into the middle dose group and high dose group , and were treated with 500 000 U, 1 000 000 U urokinase treatment , the occurrence of clinical efficacy , NHISS score and adverse reaction were compared between the two groups .Results The total efficiency of middle dose guoup was 86.67%, high dose group was 91.11%, the difference was not significant be-tween the two groups ( P>0.05 ); NIHSS score of middle dose group before thrombolysis , after 6 h, 10 d, were (8.64 ±3.61), (6.88 ±6.03), (5.91 ±6.48) points,the high dose group were (8.58 ± 3.24), (6.94 ±6.31), (6.03 ±6.44), the differences were not significant between the two groups ( P>0.05 ); the incidence of adverse reactions had no significant difference between the two groups ( P>0.05 ) .Conclusions The effect of middle and high dose urokinase on patients with 6 h acute cere-bral infarction were significant , can improve the nerve defect , but middle dose urokinase has low inci-dence of adverse reactions , should be the preferred treatment .
